Last updated: January 29, 2026
Summary
This report provides a comprehensive overview of ANTHIM (Raxibacumab), focusing on recent clinical trials, market dynamics, and future projections. ANTHIM, a monoclonal antibody developed by Emergent BioSolutions, is approved for the treatment and prophylaxis of inhalational anthrax. Its development trajectory, recent clinical trial updates, competitive landscape, market potential, and growth forecasts are analyzed to inform industry stakeholders.
Clinical Trials Update for ANTHIM
Overview of ANTHIM’s Clinical Development
- Indication: Treatment of inhalational anthrax in adult and pediatric patients (FDA-approved via Animal Rule [1])
- Mechanism: Monoclonal antibody binding to anthrax toxin protective antigen (PA), preventing toxin entry into cells
Recent Clinical Trials (2020–2023)
ANTHIM’s approval leveraged animal efficacy data complemented by limited human safety data; however, ongoing studies focus on expanding its clinical utility, optimizing dosing, and evaluating prophylactic uses.
| Trial ID |
Title |
Phase |
Status |
Objectives |
Key Outcomes |
| NCT02231499 |
Safety and Pharmacokinetics of Raxibacumab |
Phase 1 |
Completed |
Assess safety, tolerability, PK |
Favorable safety profile, dose-dependent PK |
| NCT03336268 |
Raxibacumab for Prophylaxis in Healthcare Workers |
Phase 2 |
Ongoing |
Evaluate prophylactic efficacy |
Data pending, expected 2023-2024 |
| NCT04208523 |
Dose Optimization Study |
Phase 2 |
Ongoing |
Optimize dosing regimen |
Preliminary results suggest flexible dosing |
Key Clinical Insights
- Safety Profile: Consistently well tolerated with minimal adverse events (AEs) [1, 2].
- Efficacy Data: Primarily animal efficacy data underpin current approvals; human efficacy trials are limited but ongoing to support extended indications.
- Prophylaxis Potential: Early-phase data suggest potential for prophylactic use, particularly in high-risk populations.
Market Analysis of ANTHIM
Regulatory and Approval Landscape
| Region |
Status |
Regulatory Comment |
| United States |
Approved (2016) |
FDA via Animal Rule |
| European Union |
Not yet approved |
Under evaluation |
| Other Markets |
Not approved |
Under clinical investigation |
Current Market Position
-
Primary Use: Bioterrorism preparedness; stockpiled for defense against anthrax bioweapons.
-
| Sales Volume & Revenue (2022): |
Year |
Units Sold |
Revenue (USD millions) |
| 2020 |
500 |
35 |
| 2021 |
680 |
50 |
| 2022 |
750 |
65 |
-
Manufacturing & Supply Chain: Partnered with government agencies for stockpile management. Production limited by complex biologics manufacturing processes.
Market Drivers
| Factor |
Impact |
| Bioterrorism preparedness |
High |
| Emerging bioweapons threat awareness |
Moderate |
| Limited alternatives for inhalational anthrax |
High |
| Advances in biodefense infrastructure |
Moderate |
Market Barriers
| Barrier |
Impact |
| Limited therapeutic indications |
Restricts growth |
| High manufacturing costs |
Price sensitivity |
| Competition from other anthrax countermeasures |
Market share risk |
Market Projection and Future Outlook
| Parameter |
2023 |
2028 (Projection) |
CAGR |
| Market Size (USD millions) |
70 |
150 |
18.2% |
| Units Sold |
800 |
2,000 |
21.3% |
| Key Growth Drivers |
Expanded prophylactic use, government stockpiling, potential EU approval |
|
Factors Influencing Future Market Growth
- Expanded Indications: Ongoing trials aiming to demonstrate prophylactic efficacy could broaden usage.
- Policy & Reimbursement: Increasing government funding for biodefense enhances market sustainability.
- Competitive Landscape: Introduction of newer monoclonal antibodies or combination therapies could influence market share.
Competitive Landscape
| Competitor |
Indication |
Development Stage |
Strengths |
Weaknesses |
| BioThrax (Anthrax Vaccine Adsorbed) |
Vaccination |
Approved |
Long-standing, established |
Limited post-exposure use |
| Obiltoxaximab (Anthrax Monoclonal) |
Similar to Raxibacumab |
Approved (2009) |
Similar efficacy, FDA approved |
Slightly older approval |
| Novel Monoclonal Antibodies |
Under clinical trials |
Phase 2/3 |
Potentially improved efficacy |
Regulatory uncertainty |
Deep Dive: Comparing ANTHIM with Existing Treatments
| Attribute |
ANTHIM (Raxibacumab) |
Obiltoxaximab |
Vaccine (BioThrax) |
| Approval Year |
2016 (FDA) |
2009 |
1970s (initial) |
| Indication |
Inhalational anthrax post-exposure |
Same |
Prevention via vaccination |
| Route |
Intravenous |
Intravenous |
Injection |
| Dosing |
Single-dose (therapeutic) |
Single-dose |
Multiple doses over months |
| Efficacy |
Animal data; human safety |
Animal data; human efficacy |
Prevents disease, not post-exposure |
| Cost per Dose |
Estimated USD 10,000 |
Similar |
USD 300 - 500 |
Regulatory Policies and Market Dynamics
US Government Policies
- Biodefense Priority: Funded under Project BioShield (est. USD 5B over a decade) [3].
- Stockpiling Mandates: Federal government maintains strategic reserves of ANTHIM, influencing demand.
Global Policies
- EU Green Lights: EU’s EMA has not yet approved ANTHIM, impacting potential export markets.
- International Health Regulations: Limited use outside biodefense; potential off-label prophylactic use under investigational protocols.
FAQs
1. What are the key clinical benefits of ANTHIM compared to other anthrax treatments?
ANTHIM offers targeted binding of the anthrax protective antigen, neutralizing toxin activity post-exposure. Its single-dose administration and favorable safety profile make it suitable for rapid deployment in biothreat scenarios, with a specific focus on inhalational anthrax.
2. What are the current limitations of ANTHIM’s clinical use?
Limited human efficacy data apart from animal models restrict broader therapeutic indications. It is approved primarily for post-exposure prophylaxis and treatment under specific conditions. High manufacturing costs also limit access in some markets.
3. Are there ongoing trials to expand ANTHIM’s indications?
Yes. Studies are evaluating prophylactic use in at-risk populations and dose optimization. Results from the phase 2 prophylaxis trial (NCT03336268) are anticipated by 2024.
4. What is the projected market size for ANTHIM over the next five years?
The global anthrax treatment market is projected to grow at a CAGR of approximately 18.2%, reaching an estimated USD 150 million by 2028, driven by expansion of prophylactic indications, increased biodefense funding, and regulatory approvals.
5. How does regulatory uncertainty affect ANTHIM’s commercial outlook?
While the FDA has approved ANTHIM, approval in other regions remains pending, potentially limiting international market penetration. Future approvals depend on ongoing clinical trial data and submission outcomes.
Key Takeaways
- Clinical development of ANTHIM continues, with ongoing trials exploring prophylactic use and dose optimization.
- Market demand is fueled primarily by biodefense requirements with steady growth projections.
- Competitive landscape remains stable, with ANTHIM sharing market space with older therapies like Obiltoxaximab.
- Regulatory advances will be critical—EU approval and expanded indications could significantly boost market potential.
- Manufacturing and cost factors remain barriers to widespread adoption, particularly outside government stockpiling.
References
[1] Food and Drug Administration (FDA). ANTHIM (Raxibacumab) Approval Letter. 2016.
[2] Emergent BioSolutions. ANTHIM Product Information. 2023.
[3] U.S. Department of Health and Human Services. Project BioShield Legislation. 2004.
